Corbus Pharmaceuticals has dosed the first patient in its TEMPO-1 trial of CRB-701 for oropharyngeal squamous cell carcinoma, opening patient enrollment in the study. The milestone advances its oncology pipeline as the company targets an unmet need in OPSCC.
published
Corbus Pharmaceuticals has dosed the first patient in its TEMPO-1 trial of CRB-701 for oropharyngeal squamous cell carcinoma, opening patient enrollment in the study. The milestone advances its oncology pipeline as the company targets an unmet need in OPSCC.
Latest documented BWB result
$TSLA · $SPY market result
Exit $TSLA PDS with a .60 profit per contract - was willing to hold if $SPY closed under the SMA 50 but not with a close above it
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.